Mutations in the enzyme glycyl-tRNA synthetase (GARS) cause motor and sensory axon loss in humans due to dose-dependent gain of function and give rise to clinical phenotypes that range from forms of CMT neuropathy to severe infantile SMA. The gene discussed is GARS1; the disease is proximal spinal muscular atrophy.